Nanosonics Limited ( (AU:NAN) ) has issued an update.
Nanosonics Limited announced a change in the director’s interest, with CEO Michael Kavanagh selling 100,000 ordinary shares to cover a tax liability from exercising company securities. Despite the sale, Kavanagh retains a significant holding of 1,256,723 shares and 1,569,840 rights, indicating continued confidence in the company’s prospects.
More about Nanosonics Limited
Nanosonics Limited operates in the healthcare industry, specializing in infection prevention solutions. The company is known for its innovative technologies, particularly in the area of ultrasound probe disinfection, and focuses on improving patient safety and healthcare outcomes.
YTD Price Performance: 67.11%
Average Trading Volume: 6,816
Technical Sentiment Signal: Sell
Current Market Cap: $958.1M
See more data about NAN stock on TipRanks’ Stock Analysis page.